Vitamin C improves endothelial function in healthy estrogen-deficient postmenopausal women

Climacteric

Volumn 6, Issue 3, 2003, Pages 238-247

  McSorley, P T ^a,b   Young, I S ^c   Bell, P M ^c   Fee, J P H ^c   McCance, D R ^b  

^a ALTNAGELVIN HOSPITAL   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Antioxidant; Endothelium; Plasminogen activator inhibitor 1; Postmenopause; Vitamin C

Indexed keywords

ACETYLCHOLINE; ANTIOXIDANT; ASCORBIC ACID; ESTRADIOL; ESTROGEN; FIBRINOGEN; NITROPRUSSIDE SODIUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; VASODILATOR AGENT; VON WILLEBRAND FACTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD; BLOOD VESSEL FUNCTION; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM; ESTROGEN DEFICIENCY; FEMALE; FOREARM; FOREARM BLOOD FLOW; HOMEOSTASIS; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; INSULIN RESISTANCE; INTRAARTERIAL DRUG ADMINISTRATION; METABOLISM; NUTRITIONAL DEFICIENCY; PHYSIOLOGY; PLETHYSMOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN DETERMINATION; VASCULAR ENDOTHELIUM; VASCULARIZATION; VASODILATATION;

EID: 0141727792     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/cmt.6.3.238.247     Document Type: Article

References (43)

1. Mosca L. Estrogen and atherosclerosis. J Invest Med 1998;46:381-6
2. Guetta V, Cannon RO. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation 1996;93:1928-37
3. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-11
4. McManus J, McEneny J, Young IS, Thompson W. The effect of various oestrogens and progestogens on the susceptibility of low density lipoproteins to oxidation in vitro. Maturitas 1996;25:125-31
5. Sack MN, Rader DJ, Cannon RO III. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994;343:269-70
6. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (London) 1987;362:801-9
7. Diaz MN, Frei B, Vita JA, Keaney JF. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997;337:408-16
8. Heitzer T, Just H, Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996;94:6-9
9. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF, Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;93:1107-13
10. Ting HH, Timmimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes. J Clin Invest 1996;97:22-8
11. Gokce N, Keaney JF Jr, Frei B, et al. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1999;99:3234-40
12. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-8
13. Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol 1994;73:951-2
14. Taddei S, Virdis A, Ghiadoni L, et al. Menopause is associated with endothelial dysfunction in women. Hypertension 1996;28:576-82
15. Guetta V, Cannon RO. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation 1996;93:1928-37
16. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990;81:1680-7
17. Gilligan DM, Quyyumi AA, Cannon RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994;89:2545-51
18. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994;90:786-91
19. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994;121:936-41
20. Reis SE, Gloth ST, Blumenthal RS, et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994;89:52-60
21. McCrohon JA, Adams MR, McCredie RJ, et al. Hormone replacement therapy is associated with improved arterial physiology in healthy postmenopausal women. Clin Endocrinol 1996;45:435-41
22. Koh KK, Blum A, Hathaway L, et al. Vascular effects of estrogen and vitamin E therapies in postmenopausal women. Circulation 1999;100:1851-7
23. Virdis A, Ghiadoni L, Pinto S, et al. Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women. Circulation 2000;101:2258-63
24. Saltin B, Grimby G. Physiological analysis of middle-aged and old former athletes. Circulation 1968;38:1104-15
25. McAllister AS, Atkinson AB, Johnston GD, McCance DR. Endothelial function in offspring of type 1 diabetic patients with and without diabetic nephropathy. Diabetic Med 1999;16:298-303
26. Hokanson DE, Sumner DS, Stranness DEJ. An electrically calibrated plethysmograph for direct measurement of limb blood flow. IEEE Trans Biomed Eng 1975;22:25-9
27. Whitney RJ. The measurement of volume changes in human limbs. J Phys (London) 1953;121:1-27
28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
29. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990;300:230-5
30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19
31. Trout DL. Vitamin C and cardiovascular risk factors. Am J Clin Nutr 1991;53:3225-55
32. Cleland SJ, Petrie JR, Ueda S, Elliott HL, Connell JM. Insulin as a vascular hormone: implications for the pathophysiology of cardiovascular disease. Clin Exp Pharmacol Physiol 1998;25:175-84
33. Chowienczyk PJ, Watts GF, Cockcroft J, Ritter JM. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet 1992;340:1430-2
34. Huang M, Li J, Teoh H, Man RY. Low concentrations of 17β-estradiol reduce oxidative modification of low-density lipoproteins in the presence of vitamin C and vitamin E. Free Radic Biol Med 1999;27:438-41
35. Briggs M, Briggs M. Vitamin C requirements and oral contraceptives. Nature (London) 1972;238:277
36. Vihtamaki T, Parantainen J, Koivisto AM, Metsa-Ketela T, Tuimala R. Oral ascorbic acid increases plasma oestradiol during postmenopausal hormone replacement therapy. Maturitas 2002;42:129-35
37. Jackson TS, Xu A, Vita JA, Keaney JF. Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations. Circ Res 1998;83:916-22
38. Heller R, Mtinscher-Paulig F, Gräbner R, Till U. L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells. J Biol Chem 1999;274:8254-60
39. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Am Med Assoc 1995;273:199-208
40. Gebara OC, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995;91:1952-8
41. Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in cardiovascular disease. J Invest Med 1998;46:370-6
42. Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997;336:683-90
43. Woodhouse PR, Meade TW, Khaw KT. Plasminogen activator inhibitor-1, the acute phase response and vitamin C. Atherosclerosis 1997;133:71-6